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Abstract
Background: Gastric carcinoma is the second leading cause of cancer-associated death worldwide. The high mortality
associated with this disease is in part due to limited knowledge about gastric carcinogenesis and a lack of available
therapeutic and prevention strategies. MUC1 is a high molecular weight transmembrane mucin protein expressed at the
apical surface of most glandular epithelial cells and a major component of the mucus layer above gastric mucosa.
Overexpression of MUC1 is found in approximately 95% of human adenocarcinomas, where it is associated with oncogenic
activity. The role of MUC1 in gastric cancer progression remains to be clarified.
Methodology: We downregulated MUC1 expression in a gastric carcinoma cell line by RNA interference and studied the
effects on cellular proliferation (MTT assay), apoptosis (TUNEL assay), migration (migration assay), invasion (invasion assay)
and aggregation (aggregation assay). Global gene expression was evaluated by microarray analysis to identify alterations
that are regulated by MUC1 expression. In vivo assays were also performed in mice, in order to study the tumorigenicity of
cells with and without MUC1 downregulation in MKN45 gastric carcinoma cell line.
Results: Downregulation of MUC1 expression increased proliferation and apoptosis as compared to controls, whereas cell-
cell aggregation was decreased. No significant differences were found in terms of migration and invasion between the
downregulated clones and the controls. Expression of TCN1, KLK6, ADAM29, LGAL4, TSPAN8 and SHPS-1 was found to be
significantly different between MUC1 downregulated clones and the control cells. In vivo assays have shown that mice
injected with MUC1 downregulated cells develop smaller tumours when compared to mice injected with the control cells.
Conclusions: These results indicate that MUC1 downregulation alters the phenotype and tumorigenicity of MKN45 gastric
carcinoma cells and also the expression of several molecules that can be involved in tumorigenic events. Therefore, MUC1
should be further studied to better clarify its potential as a novel therapeutic target for gastric cancer.
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Introduction
Gastric cancer is one of the most common and life-threatening
cancers worldwide (for review see [1]).The poor prognosis of this
disease reflects our poor understanding of its etiological factors and
pathogenesis and the lack of effective treatments.
MUC1 is a high molecular weight transmembrane protein that
is expressed at the apical surface of most glandular epithelial cells
[2]. MUC1 is overexpressed in almost 95% of cancer cells [3], a
molecular pathological feature that is associated with carcinogen-
esis and poor prognosis [4,5,6,7,8]. Moreover, aberrant glycosyl-
ation and loss of apical expression of MUC1 have been reported
for gastric carcinomas [9,10,11].
MUC1 protein consists of a highly variable extracellular domain
composed of a variable number of tandem repeats (VNTR), and a
highly conserved cytoplasmic domain (CD), which are both
essential for MUC1-driven oncogenic activities [12,13]. The
MUC1 extracellular domain can be extensively glycosylated [14]
and was shown to interact with several extracellular ligands,
including ICAM-1[15] and galectin-3[16]. These interactions
influence cell adhesion [16], motility and migration [17,18],
metastasis [19] and cell-cell aggregation [20], which contribute to
the maintenance of a normal cell phenotype, and upon
disregulation contribute to tumor progression. The MUC1
cytoplasmic domain (MUC1-CD) engages in signal transduction
through several residues that can be phosphorylated by receptor
tyrosine kinases (and other kinases), which in turn regulate MUC1-
CD affinity to other mediators of signal transduction and
transcriptional regulation [for review see [21] and [22]. MUC1-
CD associates with molecules such as b-catenin, c-Src, Grb2/Sos,
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Lck and Zap 70 [24] , ER-a [25], NFKb [26], c-Abl [27], ATM
[28] and CAML [29], that regulate processes of cell survival,
proliferation, apoptosis, adhesion, migration and cell-cell aggre-
gation. These functions of MUC1 are known to contribute to
tumor progression and poor survival of cancer patients [for review
see [6,30]. Nonetheless, the relevance of MUC1 in gastric cancer
progression has not been previously investigated.
In the report presented here we used retrovirus-mediated
transfection of short-hairpin RNAs (shRNA) to induce a stable
downregulation of MUC1 in the gastric carcinoma- derived cell
line MKN45. The effects of MUC1 downregulation were studied
in vitro with respect to cell proliferation, apoptosis, migration,
invasion and cell-cell aggregation. MUC1 downregulated cells
were more proliferative and apoptotic than the controls and
exhibited lower degrees of cell-cell aggregation. No significant
differences were found in terms of cell migration and invasion.
Global gene expression analysis, evaluated by oligonucleotide
microarrays, identified several genes influenced by MUC1
downregulation that may contribute to the observed phenotypic
alterations. In vivo studies have shown that MUC1 downregulation
impacts tumor development.
Materials and Methods
Cell culture
A human cell line derived from diffuse-type gastric carcinoma –
MKN45 (poorly differentiated adenocarcinoma, Japan Health
Sciences Foundation [31]) was grown in RPMI 1640 containing
Glutamax
TMI and 25mM HEPES, supplemented with 10% fetal
bovine serum (FBS) and 50 mg/ml gentamicin (Invitrogen). The
packaging cell line PhoenixGP [32] was maintained in Dulbecco’s
Modified Eagle Medium containing Glutamax
TMI, 4,500 mg/l D-
Glucose and Sodium Pyruvate, supplemented with 10% FBS and
1% (v/v) penicillin/streptomycin. Stable MUC1 downregulated
clones derived from MKN45 cells were grown in standard growth
medium supplemented with 5 mg/ml puromycin (Sigma). After
evaluation of MUC1 levels at different time points in culture, all
the assays were performed considering the time of cell culture in
which the downregulation was higher, at 96 hours of cell culture.
Cells were grown at 37uC with 5% CO2 in humidified
atmosphere.
MUC1 downregulation strategy
MUC1 downregulated cells were produced using a retroviral
expression system with short hairpin RNAs. Briefly, a 21-
nucleotide sequence of the MUC1 gene, with no homology to
other DNA sequences detected in a BLAST search, was chosen
according to standard RNAi rules [33]. The scramble control was
designed and tested for homology in a BLAST search as well.
Sense and antisense oligos (Proligo) were ligated and inserted in
the pSUPER.retro.puro vector (Oligoengine). The oligos used
were the following: MUC1 Exon 2 (sense: GATCCCCACCTC-
CAGTTTAATTCCTCTTCAAGAGAGAGGAATT AAACT-
GGAGGTTTTTTA; antisense: AGCTTAAAAAACCTCCAGT-
TTAATTCCTCTC TCTTGAAGAGGAATTAAACTGGAG-
GTGGG; the MUC1-cDNA target region is underlined) and
scramble control (sense: GATCCCCATCACCTTCGTACT-
CCTTA TTCAAGAGATAAGGAGTACGAAGGTGATTT-
TTTA, antisense: AGCTTAAAAAATC ACCTTCGTACTCCT-
TATCTCTTGAATAAGGAGTACGAAGGTGATGGG; the
‘‘unpaired’’-cDNA target region is underlined). The MUC1
specific target or the scrambled control constructs were transfected
into PhoenixGP packaging cell line by calcium-phosphate
mediated transfection and transfected cells were selected using
puromycin. Stable transfectants were seeded in a 6-well plate
(1x10
6cells/well) and incubated for 24 hours at 32uC. The media
containing the virus was collected, filtered through a 0.45 mm filter
to remove remnant cells, and used to infect MKN45 cells, during
24 hours at 37uC. The viral supernatant was then replaced by the
standard growth medium and cells were incubated 48 hours at
37uC. Efficiently transduced cells were selected and grown in
standard media supplemented with puromycin. Two independent
MUC1 downregulated clones (C1 and C2) were isolated and
expanded for three times using cloning rings.
Immunofluorescence
MKN45 cells at 96h in culture were harvested, seeded in 12-
well slides (Cell Line) and air-dried overnight at room tempera-
ture. Cells were then fixed in ice cold acetone for 5 minutes,
washed twice with PBS and blocked with normal rabbit serum
(DAKO) diluted 1:5 in 10% bovine serum albumin (BSA) for
30 minutes. Serum was then replaced by the MUC1 monoclonal
antibody HMFG1 (NovoCastra) diluted 1:50 in 5% BSA, and
incubated overnight at 4uC. After three washes with PBS, cells
were incubated with a rabbit anti-mouse FITC labeled antibody
(DAKO) diluted 1:70 in 5% BSA for 30 minutes in the dark at
room-temperature. Cells were washed 3 times with PBS and
mounted in vectashield (Vectorlabs). Images were acquired in a
Leica DMIRE2 fluorescent microscope. Results are representative
of three independent experiments.
Protein extraction and Western blot
MKN45 cells were cultured in 60-mm dishes to 80–90%-
confluence at 96h in culture. After washing twice with PBS, lysis
buffer (10mM Tris pH 7.4, 150mM NaCl, 0.1% (p/v) SDS, 1mM
PMSF, 1% (v/v) Triton X-100) was added and cells were scraped.
Lysates were incubated on ice for 1 hour and centrifuged for
2 minutes at 4uC to collect the supernatants. Protein content was
assessed by the bicinchoninic acid method (Pierce), as described in
the manufacturer’s instruction manual. Protein extracts were
analyzed by a 4–10% SDS-PAGE (Invitrogen), transferred to a
nitrocellulose membrane (Amersham Biosciences), and blotted
overnight at 4uC with anti MUC1-Ab5 monoclonal antibody
(1:300, ThermoScientific), anti-beta-actin polyclonal antibody
(1:8,000, Sigma), anti ERK1/2(1:1,000, Cell Signaling Technol-
ogy) and anti b-catenin (1:1,000, BD Transduction Laboratories)
in 5% non-fat milk in TBS-0.1%Tween20 (Sigma). Membranes
were washed 3 times with TBS-0.1%Tween20 and the primary
antibodies were revealed using goat anti-mouse peroxidase-
conjugated antibody (1:1,000, DAKO) in 5% non-fat milk in
TBS-0.1%Tween20, followed by ECL detection kit (BioRad).
Results are representative of three independent experiments.
RNA extraction and Real-Time PCR
Total RNA was isolated from MKN45 cells at 96h in culture
using TriReagent
TM (Sigma), according to the manufacturer’s
instructions. 5 mg of RNA were primed with random hexamers
(Invitrogen) and reverse transcribed with Superscript II (Invitro-
gen) in a final volume of 20 ml. 2 ml of a 1:10 dilution of cDNA
were amplified with 300nM of each primer and SYBRGreen
(Applyed BioSystems) in a final volume of 20 ml, using the
fluorescence reader ABI Prism 7000. Each sample was run in
duplicate. The primers used were the following: MUC1 (sense:
CTCCTTTCTTCCTGCTGCTG, antisense: CTGGAGAGTA-
CGCTGCTGGT) and 18S (sense: CGCCGCTAGAGGTGA-
AATTC, antisense: CATTCTTGGCAAATGCTTTCG), and
their specificity was confirmed using the software BLASTn on-
MUC1 Impact in Gastric Tumorigenesis
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e26970line and by melt curve analysis. For each sample, the level of 18S
RNA was measured and used for normalization of target genes
abundance. Relative mRNA levels were then calculated using the
comparative Ct method [34]. Data is expressed as a ratio of the
results obtained with each clone and the scramble control, from
three independent experiments. Statistical analysis was performed
using the Mann-Whitney test.
MTT proliferation assay
Cells were plated in triplicate in 96-well plates at 5,000 cells per
well and incubated at normal conditions for 96h for MKN45 cells.
At each time point, the medium was removed and cells incubated
with 20 ml of MTT solution (5mg/ml, Sigma) for 3 hours at
normal conditions. MTT was removed and 200 ml of DMSO were
added to each well to dissolve formazan. Finally, formazan optical
density was measured using a microplate reader at a wavelength of
540nm. The relative growth was defined as the following formula:
Relative Growth = (A540nm at Tn / A540nm at T024h). Data is
expressed as a ratio of the results obtained with each clone and the
scramble control, from three independent experiments. Statistical
analysis was performed using the Mann-Whitney test.
Terminal Transferase dUTP Nick End Labeling (TUNEL)
assay
Post-confluent cells at 96h in culture were harvested and fixed
with 4% paraformaldehyde in PBS for 15 minutes. Fixed cells
were seeded in 12-well slides (Cell Line) and air-dried overnight at
room temperature. Following washing with PBS, cells were
permeabilized with ice-cold freshly-made PBSTrCit solution
(PBS + 0.1%TritonX + 0.1% Sodium Citrate) for 2 minutes on
ice. Cells were washed again twice, and incubated with TUNEL
reaction mix (enzyme solution, label solution and dilution buffer,
Figure 1. MUC1 downregulation by shRNA. (A) MUC1 detection by immunofluorescence with HMFG-1 antibody in MKN45-C1 and MKN45-C2
and MKN45-SC control; (B) MUC1 protein detection by western-blot with MUC1-Ab5 antibody of total protein extracts from MKN45-C1 and MKN45-
C2 and MKN45-SC control; (C) Quantification of MUC1 RNA in MKN45-C1 and MKN45-C2 and MKN45-SC control by real-time PCR. MUC1 expression
was corrected to the house-keeping gene 18S and normalized to the data obtained with the scrambled control. *P,0.01.
doi:10.1371/journal.pone.0026970.g001
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hour at 37uC. Two additional washing steps were performed and
slides were mounted in Vectashield with DAPI (Vectorlabs).
Results were analyzed under a Leica DMIRE2 fluorescent
microscope and data is expressed as a ratio of the results obtained
with each clone and the scramble control, from three independent
experiments. Statistical analysis was performed using the Mann-
Whitney test.
Migration assay
MKN45 cells were cultured in 60-mm dishes for a full-
confluence at 96h in culture. The epithelial cells monolayer was
then washed with PBS and wounded with a 10 ml micropipette tip.
Non-adherent cells were removed by washing twice with PBS.
Images of cells at the edge of the wound were acquired
automatically at 20x magnification in a Leica DMIRE2
fluorescence microscope with a Leica DFC Twain camera for
144 frames at 10-minute intervals (corresponding to 24 hours)
controlled by Leica FW4000 software. Frames from 0, 6, 12, 18
and 24 hours were used to quantify the percentage of migration: a
grid of 50x30 squares was used to fulfill the wound space and the
percentage of migration was calculated by the number of squares
occupied by cells at each time point. Data is expressed as a ratio of
the results obtained with each clone and the scramble control,
from three independent experiments. Statistical analysis was
performed using the Mann-Whitney test.
Matrigel invasion assay
Cell invasion was studied by using BD Biocoat
TM Matrigel
TM
invasion chambers with 8-mm size pores (BD Biosciences),
according to the manufacturer’s instructions. MKN45 cells at
96h in culture were harvested and seeded in duplicate at 250,000
cells per insert (sized for 24-well plates) in 1% FBS containing
medium, and 20% FBS containing medium was added to the
bottom of the growth well, as an attractant. Cells were allowed to
invade for 22 hours (37uC, 5% CO2 atmosphere). The non-
invading cells were then swabbed from the top of the inserts and
the invading cells on the lower surface were fixed with 100%
methanol and stained with DAPI for 15 minutes in the dark. The
membranes were removed and cells were counted under a Leica
DMIRE2 fluorescence microscope. Data are expressed as a ratio
of the results obtained with each clone and the scramble control,
from three independent experiments. Statistical analysis was
performed using the Mann-Whitney test.
Cell-cell Aggregation assay
MKN45 cells at 96h in culture were harvested and seeded in
duplicate at 250,000 cells per well in 24-well plates. Plates were
placed at 37uC with constant stirring (150rpm) for 1 and 2 hours.
Cells were fixed with 100 ml of 25% glutaraldehyde at time zero
and at the end of the incubation. Aggregates were photographed
under a light microscope and isolated cells were counted (cells in
duplicates were counted as isolated cells). The aggregation index
was defined as the following formula: Aggregation index =1-
(number of isolated cells at Tn / number of isolated cells at T0).
Data are expressed as a ratio of the results obtained with each
clone and the scramble control, from three independent
experiments. Statistical analysis was performed using the Mann-
Whitney test.
Gene expression analysis
The expression of 12,135 genes in MUC1 downregulated clones
and the respective scramble control were evaluated following the
same protocol as before [35]. Briefly, following RNA extraction (as
described previously), cDNA was obtained by reverse transcrip-
tion, during which labeled nucleotides were incorporated:
MKN45-C1 and MKN45-C2 cDNAs were labeled with Cy3
(green emission) and MKN45-SC control with Cy5 (red emission).
After hybridization, the mixture was hybridized with the array
overnight and then the array was digitalized with the ScanAr-
ray4000 (Perkin-Elmer) system and fluorescence analyzed by the
QuantArray software package (Perkin-Elmer).
Normalization and background subtraction were performed
and ratios for downregulated clones /Scrambled Control and
Scrambled Control/downregulated clones were calculated using
Microsoft Excel software. Gene expression with a ratio higher than
2 was considered statistically significant.
All data is MIAME compliant and that the raw from the
microarray experiments were uploaded onto the Gene Expression
Omnibus Database http://www.ncbi.nlm.nih.gov/geo (Geo ac-
cession numbers: GSM717858 and GSM717859).
In Vivo tumor growth Assays
Six-week-old female N:NIH(s)II:nu/nu nude mice were ob-
tained previously from the Medical School, University of Cape
Town in 1991 and maintained and housed at IPATIMUP Animal
House at the Medical Faculty of the University of Porto, in a
pathogen-free environment under controlled conditions of light
Figure 2. Quantification of cell proliferation by MTT assay.
Quantification of metabolically active cells by MTT assay in MKN45-C1
and MKN45-C2 clones and MKN45-SC control at 96h in culture. Data
from 24 hours was used to set time zero and results were normalized to
the data obtained with the scrambled control.*P,0.01.
doi:10.1371/journal.pone.0026970.g002
Figure 3. Quantification of apoptotic cells by TUNEL assay.
Apoptosis of MKN45-C1 and MKN45-C2 and scramble control (SC) were
evaluated at 96h in culture by the TUNEL assay. Results were
normalized to the data obtained with the scrambled control. *P,0.01.
doi:10.1371/journal.pone.0026970.g003
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vivo experiments. Animal experiments were carried out in
accordance with the Guidelines for the Care and Use of
Laboratory Animals, directive 86/609/EEC. Mice were subcuta-
neously injected in the dorsal flanks using a 25-gauge needle with
1x10
5 of MKN45-SC (2 male and 2 female mice) or MKN45-C2
cells (3 male and 3 female mice). Mice were weighed, and tumor
width and length were measured with calipers every week. Mice
were euthanized 21 days after cell injection, at the time when the
first tumor reached maximum allowable volume. For statistical
analysis, the Mann Whitney test-StatView Software version 5.0
(SAS Institute, Cary, NC) was used. A P value of less than 0.05 was
considered as statistically significant.
Results
MUC1 downregulation by shRNA
We established two independent MUC1 downregulated clones,
MKN45-C1 and MKN45-C2 and one scramble control, MKN45-
SC. MUC1 downregulation was verified by immunofluorescence
(Figure 1A), Western Blot (Figure 1B) and Real-Time PCR
(Figure 1C).
There was a significant downregulation of MUC1 expression in
MKN45-C1 and MKN45-C2 clones as compared to the MKN45-
SC control. The expression of MUC1 at the protein level was
detected with two different antibodies, one that binds the VNTR
extracellular domain (HMFG-1, Figure 1A) and other that
recognizes a 14–28 KDa sequence in MUC1 cytoplasmic domain
(MUC1-Ab5, Figure 1B). Both showed a significant reduction in
the amount of MUC1 protein in MKN45-C1 and MKN45-C2
clones when compared to the scramble control. Real-Time PCR
results indicate that the MUC1 downregulation was 48%
(MKN45-C1) and 38% (MKN45-C2) (Figure 1C). MUC1 RNA
levels were evaluated at 48, 72 and 96h of cell culture and the
highest downregulation occurred at 96h (results not shown).
Effects of MUC1 downregulation on MKN45 cells
Cell proliferation. MKN45-C1 and MKN45-C2 cells
showed significantly increased proliferation rates (P,0.01) when
Figure 4. Quantification of cell-cell aggregation. (A)Quantification of the cell-cell aggregation index in MKN45-C1 and MKN45-C2 and MKN45-
SC control. The cell-cell aggregation index was assessed by the observed decrease in the number of isolated cells over time, and normalized to the
data obtained with the scrambled control. *P,0.01; (B) Images of the aggregates formed after 1 and 2 hours of constant stirring. First column shows
isolated cells at time 0h (20x magnification) and second and third columns show aggregates formed after 1h and 2h of incubation (40x
magnification), in MKN45-C1 and MKN45-C2 and MKN45-SC control.
doi:10.1371/journal.pone.0026970.g004
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evaluated by MTT assay (Figure 2).
Cell apoptosis. MKN45-C1 and MKN45-C2 cells showed
significantly increased levels of apoptosis (P,0.01) when compared
to the MKN45-SC control (3.32 and 2.41 vs 1), when evaluated by
a TUNEL assay (Figure 3).
Cell-cell aggregation. MKN45-C1 and MKN45-C2 cells
showed significantly decreased cell-cell aggregation levels
(P,0.01), when compared to the MKN45-SC control (0.34 and
0.49 vs 1 at 1h; 0.52 and 0.64 vs 1 at 2h), when evaluated by a cell
aggregation assay (Figures 4A and 4B).
Cell migration and invasion. There were no significant
differences in cell migration and invasion of MKN45-C1 and
MKN45-C2 cells when compared to the MKN45-SC control,
when evaluated by motility and invasion assays (results not shown).
Effects of MUC1 downregulation in MKN45 cells gene
expression
The observed phenotypic modifications associated were likely
due in part to alterations in signal transduction pathways mediated
by MUC1-CD, since overexpression of MUC1 has been shown to
modulate gene expression through reprograming transcription of
multiple genes [36,37]. We evaluated the net effects of
downregulating MUC1 in the MKN45 gastric carcinoma cell
line by performing a global analysis of gene expression by
oligonucleotide microarrays (Table 1). The results revealed that a
number of genes that influence proliferation, migration, invasion
and motility were differentially expressed in MKN45-C1 and
MKN45-C2 and the MKN45-SC control. The most significant
differences were found for TCN1, KLK6 and ADAM29 (.10 fold
upregulated between the MKN45-C1 and MKN45-C2 clones and
the MKN45-SC control) and LGALS4, TSPAN8 and SHPS-1
(.3.5 fold downregulated between the MKN45-C1 and MKN45-
C2 clones and the MKN45-SC control).
In vivo tumor growth assays
In vivo tumorigenicity assays showed that mice injected with
MUC1-downregulated cells (MKN45-C2) developed smaller and
slower-growing tumors, when compared to mice injected with the
MKN45-SC control cells (Figure 5).
Discussion
In the work presented here, we evaluated the effects of MUC1
downregulation on cancer-related properties of MKN45 gastric
carcinoma cells. Stable downregulation of MUC1 expression was
achieved in MKN45 gastric carcinoma cell line by RNA
interference. MUC1 contributes to tumor progression of adenocar-
cinomasand thereforeitsdownregulation waspredictedtoaffectthe
malignant properties of cancer cells, including proliferation,
apoptosis, migration, invasion and cell-cell aggregation.
We found that proliferation was significantly increased in MUC1
downregulated clones MKN45-C1 and MKN45-C2 when compared
to the control MKN45-SC. Similar studies with breast and pancreatic
carcinoma cell lines have shown similar [38] and opposite [35,38,39]
results. In different tumor models, MUC1 was shown to regulate cell
proliferation by interacting with several proteins such as ER-a, b-
catenin and EGFR [25,40,41]. However, for gastric carcinoma cells,
such interactions have not been investigated. Results obtained by an
oligonucleotide microarray analysis showed that expression of
molecules affecting cell proliferation such as KLK6 and LGAL-4
[42,43,44] were significantly altered in MKN45-C1 and MKN45-C2
clones when compared to the MKN45-SC control. KLK6 expression
was increased in MKN45-C1 and MKN45-C2 clones, whereas
LGAL4 expression was decreased and these differences may explain
the observed differences in proliferation. The mechanisms by which
KLK6 and LGAL4 expression is altered in MKN45-C1 and MKN45-
C2 when compared to MKN45-SC control remains to be elucidated.
Another important observation was that apoptosis was signif-
icantly increased in MKN45-C1 and MKN45-C2 clones when
compared to the MKN45-SC control. MUC1 was previously
shown to mediate a pro-apoptotic response in hamster ovary cells
[45] and it was also attributed with anti-apoptotic functions in
Table 1. Oligonucleotide microarray results by comparison
between MKN45-C1/MKN45-C2 and MKN45-SC control cells,
by order of magnitude.
Genes upregulated .2 fold in MUC1 downregulated clones
Transcobalamin 1 (TCN1)
Kallikrein-related peptidase 6 (KLK6)
Desintegrin and metalloproteinase 29 (ADAM29)
Keratoepithelin (TGFBI)
MRP family of ATP transport member 2 (ABCC2)
Amyloid beta precursor-like protein 2 (APLP2)
Mitochondrial ATP synthase (ATP5I)
Sulfide dehydrogenase like protein (SQRDL)
Sarcoglycan, epsilon (SGCE)
Hypothetical protein (FLJ20323)
Galectin 1 (LGALS1)
Proline-histidine rich protein (PHLDA1)
Trypsin 2 (PRSS2)
Mesotrypsin (PRSS3)
SP2 transcription factor (SP2)
Ubiquitin-conjugating enzyme (UBE2L6)
Vitellogenic-like carboxypeptidase (CPVL)
Genes downregulated .2 fold in MUC1 downregulated clones
Galectin 4 (LGALS4)
Tetraspanin 8 (TSPAN8)
Tyrosine phosphatase SHP substrate (SHPS-1)
Polymerase (DNA-directed), delta 4 (POLD4)
H2B histone family, member J (HIST1H2BH)
H2B histone family, member T (HIST1H2Bk)
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Annexin IV (ANXA4)
Intercellular adhesion molecule 4 (ICAM4)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 (DDX39)
Apolypoprotein B (APOBEC2)
Clusterin (CLU)
GDP-mannose 4,6-dehydratase (GMDS)
Serine/threonine kinase 38 like (STK38L)
CD55 (CD55)
Apolipoprotein B-catalytic polypeptide-like 3C (APOBEC3C)
Cell adhesion related-molecule (CDON)
Villin-1 (VIL1)
MKN45-C1 and MKN45-C2 and the MKN45-SC control were analysed by
oligonucleotide microarrays. Listed are genes with expression increased or
decreased more than 2 fold in both MUC1 downregulated clones when
compared to the control.
doi:10.1371/journal.pone.0026970.t001
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However, little is known about the influence of MUC1 on cell
apoptosis in gastric carcinoma cells.
No significant differences were found between MUC1-C1 and
C2 clones and MKN45-SC control with respect to cell migration
and invasion. This is in contrast to previous findings in which
MUC1 was shown to influence cell migration in breast, cervical,
renal and pancreatic carcinoma cell lines [18,49,50,51] and cell
invasion in breast, lung, gastrointestinal, hepatic and pancreatic
carcinoma cell lines [3,52,53].
Cell-cell aggregation was decreased in MKN45-C1 and
MKN45-C2 clones when compared to the MKN45-SC control.
Previous studies have shown that overexpression of different forms
of MUC1 can lead to an increase or a decrease in cell-cell
aggregation in a pancreatic carcinoma cell line [54], whereas
others have shown that MUC1 downregulation induces an
increase of cell-cell aggregation in an oral carcinoma cell line
[41]. MUC1 interactions with other adhesion molecules have been
shown to contribute to both adhesive [55,56] and anti-adhesive
[57,58,59] properties of cells. Our results showed that MUC1
plays a relevant role in MKN45 cell-cell aggregation, contributing
to gastric cells adhesive properties.
Another possibility is that signaling through the MUC1-CD
influences gene expression, which in turn affects the phenotypic
properties of the MKN45 cell line. By oligonucleotide microarray
analysis we found alterations in the transcriptional profile of cells
following MUC1 downregulation when compared to control cells.
These alterations are likely due to MUC1 downregulation, since
MUC1 has been shown to directly conduct signals that alter the
transcriptional program of tumor cells [36,37,60]. MUC1 cytoplas-
mic domain can be phosphorylated in several sites, modulating its
interaction with cell signalling partners and transcription factors [21].
The phosphorylation of MUC1-CD will be dependent on the
amount and availability of its signaling partners and therefore on the
cell type in question. We found significant alterations in the
expression levels of several genes, mainly TCN1, KLK6, ADAM29,
LGALS4, TSPAN8 and SHPS-1. Some of these molecules have
functions not yet fully clarified yet others are known to be associated
with cell proliferation and migration, including KLK6, LGAL4 and
SHPS-1 [42,43,59,61,62], invasion, including KLK6 [59] and
motility, including LGAL4 [43]. MUC1 may be facilitating the
transcription of these genes and therefore be contributing to the
observed phenotypic alterations observed.
In vivo assays confirmed that cells with decreased levels of
MUC1 form smaller and slower-growing tumors than the control
cells. This result emphasizes that MUC1 contributes to gastric
tumor progression in the context of the multicellular environment
of tumor growth in vivo.
MUC1 overexpression has been associated with the neoplastic
progression of several tumors, including the acquisition of invasive
and metastatic properties. Phenotypic studies in cell models other
than gastric cancer have suggested that MUC1 influences events
such as proliferation, apoptosis, migration, invasion, adhesion and
cell-cell aggregation. Previous studies of MUC1 in breast
carcinogenesis models show mixed results for different breast
cancer cell lines [38], which reinforces the relevance of the
molecular context on the MUC1-mediated cancer progression.
The effects of MUC1 in gastric carcinogenesis will thus be
dependent on MUC1 and the molecules interacting with MUC1,
which will significantly differ between cell lines. Evaluation of
different gastric cell lines will complement the data regarding the
impact of MUC1 gastric carcinogenesis.
The work presented here shows for the first time that MUC1
expression influences proliferation, apoptosis and cell-cell aggre-
gation of MKN45 gastric carcinoma cells. The results are
consistent with the view that MUC1 modulates different signaling
pathways in a manner that is dependent on the expression and
activity of other regulatory mechanisms and molecules, which are
influenced by the cellular and biological context of the cell type
that is overexpressing MUC1.
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